Skip to content

Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA)

Postoperative Exercise Training in Patients With Colorectal Liver Metastases Undergoing Surgery (ELMA)

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04751773
Acronym
ELMA
Enrollment
60
Registered
2021-02-12
Start date
2021-03-12
Completion date
2026-03-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Liver Metastasis

Keywords

Aerobic exercise, Resistance exercise, Perioperative medicine, Prehabilitation, Rehabilitation, Cancer, Surgical oncology, Surgery, Exercise oncology

Brief summary

Surgery is a primary treatment modality in the intended curative treatment of colorectal liver metastases (CRLM). However, surgery elicits a cascade of potentially detrimental stress responses that may drive the onset of long-term disease progression. Exercise training is emerging as an adjunct treatment in surgical oncology and holds potential to modify the surgical stress response. Against this background, we designed the present randomized controlled trial to evaluate the therapeutic role of pre- and postoperative exercise training in patients with CRLM undergoing open liver resection.

Detailed description

BACKGROUND: Colorectal cancer is the third most frequent type of cancer in Denmark, with more than 5000 new cases annually. Colorectal liver metastases (CRLM) develop in nearly one fourth of all patients with colorectal cancer, and poses a poor prognostic outlook, with low survival rates and short time to disease progression. Surgical resection, either upfront or following downstaging with perioperative treatments, confers substantial survival benefit in patients with CRLM, and may even comprise a curative treatment modality. However, surgery elicits a cascade of biological responses characterized by increased dissemination of tumor cells and modulation of neuroendocrine, inflammatory, and immunological factors. These local and systemic perturbations typically persist for days to weeks following surgery and may independently or in concert drive the onset of long-term disease progression. Under normal physiological conditions, exercise training is a potent modulator of immune function, systemic inflammation, and the neuroendocrine system, raising the possibility that perioperative exercise training may ameliorate the surgical stress response during and after surgery. However, in a recent systematic review and meta-analysis (submitted), we found that the effects and safety of preoperative and early postoperative exercise are unknown in patients with gastrointestinal cancers (including CRLM) due to lack of studies, widespread methodological issues, and poor ascertainment and reporting of adverse events. Safety is arguably the single most important consideration for the application perioperative exercise, and methodological robust trials evaluating the safety and tolerability of perioperative exercise training along with preliminary information on treatment efficacy are needed to inform the application of exercise in surgical oncology. Against this background, we designed the present randomized controlled trial to evaluate the therapeutic role of postoperative exercise training in patients with CRLM undergoing open liver resection. The primary trial objective and hypothesis are: 1. To compare the number of serious adverse events (SAE) in standard care plus postoperative exercise (EX) vs. standard care alone (CON) in patients with colorectal liver metastases scheduled to undergo open liver resection. The primary research hypothesis is that the number of SAEs is non-inferior in EX vs. CON The key secondary study objectives and hypotheses are: 2. To compare the effect of EX vs. CON on incidence of postoperative hospital admissions in patients with CRLM undergoing surgery. We hypothesize that the incidence of postoperative hospital admissions are non-inferior in EX vs. CON 3. To compare the effect of EX vs. CON on relative dose intensity of adjuvant chemotherapy and time from surgery to initiation of adjuvant chemotherapy in patients with CRLM undergoing surgery. We hypothesize that the relative dose intensity of adjuvant chemotherapy and time from surgery to initiation of adjuvant chemotherapy are non-inferior in EX vs. CON. 4. To compare the effect of EX vs. CON on selected patient-reported symptomatic adverse events in patients with CRLM undergoing surgery 5. To compare the effect of EX vs. CON on surgical stress responses (neuroendocrine, inflammatory, and immune factors) in patients with CRLM undergoing surgery. The secondary study objectives are: 6. To evaluate the feasibility of EX. 7. To compare the effect of EX vs. CON on functional capacity, muscle strength, aerobic capacity, and body composition in patients with CRLM undergoing surgery. 8. To compare the effect of EX vs. CON on clinical outcomes in patients with CRLM undergoing surgery. 9. To compare the effect of EX vs. CON on patient-reported outcomes in patients with CRLM undergoing surgery. 10. To compare the effect of EX vs. CON on circulating tumor DNA and DNA methylation in patients with CRLM undergoing surgery 11. To evaluate the effects of acute pre- and postoperative exercise on neuroendocrine, immunological, and inflammatory factors in patients with CRLM undergoing surgery. 12. To conduct explorative preclinical sub-studies. TRIAL DESIGN: This trial is a single-center, randomized, controlled, parallel-group trial performed at Centre for physical Activity (CFAS), Rigshospitalet, Copenhagen, Denmark, and Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark. A total of 60 participants with CRLM will be included and randomly allocated 2:1 to standard care and postoperative exercise training (EX) or standard care alone (CON). The participants will undergo two trial visits at CFAS during the study period: One preoperative trial visit (1-3 days after inclusion and 2-7 days before surgery) and one post-surgery trial visit (8 weeks after discharge). For each visit, the participants will be assessed for body composition and anthropometrics, resting cardiovascular factors, standard blood biochemistry, aerobic capacity (VO2peak, ventilatory threshold), maximal muscle strength, and functional performance. In addition, blood samples will be taken before, during, and immediately after surgery, and on post-operative day 1, 3, and 15 and neuroendocrine, inflammatory, and immune factor will be analyzed. Patient-reported outcomes will be collected at all trial visits and 1, 2, and 3 years after randomization. Data from medical records regarding mortality and disease recurrence will be collected up to 3 years after randomization. As an optional procedure, we will collect blood samples before, during, and after a pre- and a postoperative supervised exercise training session.

Interventions

BEHAVIORALExercise training

Perioperative exercise training

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The participants and the exercise intervention instructors cannot be blinded, given the nature of the intervention. The outcome assessors of the primary and key secondary outcomes (adverse events and markers of surgical stress, respectively) will be blinded. For practical reasons, the outcome assessors of the following secondary outcomes will be not be blinded: resting cardiovascular factors, aerobic capacity, muscle strength, functional performance, and body composition and anthropometrics.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Participants diagnosed with colorectal liver metastasis planned for open surgery of liver metastases

Exclusion criteria

* Age \<18 * Pregnancy * Other known malignancy requiring active cancer treatment that prohibits execution of test or training procedures * Conditions that prohibit execution of trial procedures * Inability to understand the Danish language.

Design outcomes

Primary

MeasureTime frame
Serious adverse eventsFrom discharge to 8 weeks after discharge

Secondary

MeasureTime frameDescription
Relative dose intensity (RDI) of adjuvant chemotherapyFrom date of planned initiation of adjuvant chemotherapy until 8 weeks after dischargeRDI (%) of adjuvant chemotherapy, calculated as the actual dose intensity / standard dose intensity x 100%
Time to initiation of adjuvant chemotherapyFrom surgery until 8 weeks after dischargeTime from surgery to initiation of adjuvant chemotherapy
Patient-reported symptomatic adverse eventsBaseline, 7 days after discharge, 7 days after each administration of adjuvant chemotherapy, 8 weeks after discharge.Patient-reported symptomatic adverse events, assessed using the using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Surgical stress: IL-1βBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood IL-1β concentration
Surgical stress: IL-6Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood IL-6 concentration
Surgical stress: IL-8Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood IL-8 concentration
Surgical stress: IL-10Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood IL-10 concentration
Surgical stress: interferon- γBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood interferon- γ concentration
Postoperative hospital admissionsFrom discharge to 8 weeks after dischargeIncidence of postoperative hospital re-admissions, defined as any non-scheduled ≥ 24 h hospitalization
Surgical stress: Leukocyte differential countsBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood leukocyte cell counts (total and per type \[eosinophils, basophils, lymphocytes, monocytes, neutrophils\])
Surgical stress: Natural killer (NK) cellsBaseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood NK cell count
Surgical stress: T cellsBaseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood T cell count
Surgical stress: Adrenocorticotropic hormone (ACTH)After last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15Changes in blood ACTH concentration
Surgical stress: CortisolBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood cortisol concentration
Surgical stress: AdrenalineBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood adrenaline concentration
Surgical stress: NoradrenalineBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood noradrenaline concentration
Surgical stress: C-reactive proteinBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in blood C-reactive protein

Other

MeasureTime frameDescription
Resting cardiovascular factors: Resting systolic blood pressureBaseline, 8 weeks after dischargeChanges in resting systolic blood pressure
Resting cardiovascular factors: Resting diastolic blood pressureBaseline, 8 weeks after dischargeChanges in resting diastolic blood pressure
Resting cardiovascular factors: Resting heart rateBaseline, 8 weeks after dischargeChanges in resting heart rate
Resting cardiovascular factors: Hemoglobin concentrationBaseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in hemoglobin concentration
Aerobic capacity: Peak oxygen consumptionBaseline, 8 weeks after dischargeChanges in peak oxygen consumption assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion
Aerobic capacity: Ventilatory thresholdBaseline, 8 weeks after dischargeChanges in ventilatory threshold assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion
Aerobic capacity: Peak power outputBaseline, 8 weeks after dischargeChanges in peak power output assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion
Muscle strength: Leg press maximal muscle strengthBaseline, 8 weeks after dischargeChanges in leg press one repetition maximum (1RM)
Muscle strength: Chest press muscle strengthBaseline, 8 weeks after dischargeChanges in chest press 1RM
Muscle strength: Hand grip strengthBaseline, 8 weeks after dischargeChanges in hand grip strength, assessed using a dynamometer
Functional performance: Habitual gait speedBaseline, 8 weeks after dischargeChanges in habitual gait speed
Functional performance: Maximal gait speedBaseline, 8 weeks after dischargeChanges in maximal gait speed
Functional performance: Stair climbing powerBaseline, 8 weeks after dischargeChanges in stair climbing power
Body composition and anthropometrics: Body massBaseline, 8 weeks after dischargeChanges in body mass
Body composition and anthropometrics: Body mass indexBaseline, 8 weeks after dischargeChanges in body mass index
Body composition and anthropometrics: Total lean massBaseline, 8 weeks after dischargeChanges in total lean mass, assessed by dual energy x-ray absorptiometry (DXA)
Body composition and anthropometrics: Appendicular lean massBaseline, 8 weeks after dischargeChanges in appendicular lean mass, assessed by DXA
Body composition and anthropometrics: Fat percentageBaseline, 8 weeks after dischargeChanges in fat percentage, assessed by DXA
Body composition and anthropometrics: Hip circumferenceBaseline, 8 weeks after dischargeChanges in hip circumference
Body composition and anthropometrics: Waist circumferenceBaseline, 8 weeks after dischargeChanges in waist circumference
Standard blood biochemistry: Total cholesterolBaseline, 8 weeks after dischargeChanges in total cholesterol concentration
Standard blood biochemistry: Low-density lipoprotein cholesterolBaseline, 8 weeks after dischargeChanges in low-density lipoprotein cholesterol concentration
Standard blood biochemistry: High-density lipoprotein cholesterolBaseline, 8 weeks after dischargeChanges in high-density lipoprotein cholesterol concentration
Standard blood biochemistry: TriglycerideBaseline, 8 weeks after dischargeChanges in triglyceride concentration
Standard blood biochemistry: Glycated hemoglobin A1cBaseline, 8 weeks after dischargeChange in glycated hemoglobin A1c concentration
Standard blood biochemistry: InsulinBaseline, 8 weeks after dischargeChanges in insulin concentration
Standard blood biochemistry: GlucoseBaseline, 8 weeks after dischargeChanges in blood glucose concentration
Health-related quality of life: Physical well-beingBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported physical well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C)
Health-related quality of life: Social well-beingBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported social well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C)
Health-related quality of life: Emotional well-beingBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported emotional well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
Health-related quality of life: Functional well-beingBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported functional well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
Health-related quality of life: Colorectal-cancer specificBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported colorectal-cancer specific health-related quality of life assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
Health-related quality of life: GeneralBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported general health-related qualify of life assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
Health-related quality of life: Trial outcome indexBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported trial outcome index assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
Health-related quality of life: Total score (Functional Assessment of Cancer Therapy - Colorectal)Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported in health-related quality of life (total score) assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C).
DepressionBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported depression, assessed using the Hospital Anxiety and Depression Scale (HADS).
AnxietyBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported anxiety, assessed using the Hospital Anxiety and Depression Scale (HADS).
Self-reported physical activity: WalkingBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported weekly duration of walking, assessed using the International Physical Activity Questionnaire (IPAQ)
Self-reported physical activity: Moderate intensity physical activity (PA)Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported weekly duration of moderate intensity PA, assessed using the International Physical Activity Questionnaire (IPAQ)
Body composition and anthropometrics: Abdominal fat massBaseline, 8 weeks after dischargeChanges in abdominal fat mass, assessed by DXA
Self-reported physical activity: Total physical activity (PA)Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported weekly duration of total PA, assessed using the International Physical Activity Questionnaire (IPAQ)
Self-reported physical activity: Sitting timeBaseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported weekly sitting time, assessed using the International Physical Activity Questionnaire (IPAQ)
Effect of acute perioperative exercise: IL-1β10 min before exercise, immediately after aerobic exerciseChanges in blood IL-1β concentration during acute perioperative exercise
Effect of acute perioperative exercise: IL-610 min before exercise, immediately after aerobic exerciseChanges in blood IL-6 concentration during acute perioperative exercise
Effect of acute perioperative exercise: IL-810 min before exercise, immediately after aerobic exerciseChanges in blood IL-8 concentration during acute perioperative exercise
Effect of acute perioperative exercise: IL-1010 min before exercise, immediately after aerobic exerciseChanges in blood IL-10 concentration during acute perioperative exercise
Effect of acute perioperative exercise: Interferon- γ10 min before exercise, immediately after aerobic exerciseChanges in blood interferon- γ concentration during acute perioperative exercise
Effect of acute perioperative exercise: C-reactive protein10 min before exercise, immediately after aerobic exerciseChanges in blood C-reactive protein concentration during acute perioperative exercise
Effect of acute perioperative exercise: Leukocyte differential counts10 min before exercise, immediately after aerobic exerciseChanges in blood leukocyte cell counts (total and per type \[eosinophils, basophils, lymphocytes, monocytes, neutrophils\]) during acute perioperative exercise
Effect of acute perioperative exercise: Natural killer cells10 min before exercise, immediately after aerobic exerciseChanges in blood natural killer cell count during acute perioperative exercise
Effect of acute perioperative exercise: T cells10 min before exercise, immediately after aerobic exerciseChanges in blood T cell count during acute perioperative exercise
Effect of acute perioperative exercise: Adrenocorticotropic hormone (ACTH)10 min before exercise, immediately after aerobic exerciseChanges in blood ACTH concentration during acute perioperative exercise
Effect of acute perioperative exercise: Cortisol10 min before exercise, immediately after aerobic exerciseChanges in blood cortisol concentration during acute perioperative exercise
Effect of acute perioperative exercise: Adrenaline10 min before exercise, immediately after aerobic exerciseChanges in blood adrenaline concentration during acute perioperative exercise
Effect of acute perioperative exercise: Noradrenaline10 min before exercise, immediately after aerobic exerciseChanges in blood noradrenaline concentration during acute perioperative exercise
LPS-induced IL-6 production of whole bloodBaseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in concentation of IL-6 in LPS-stumulated whole blood
LPS-induced TNF-a production of whole bloodBaseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in concentation of TNF-a in LPS-stumulated whole blood
Self-reported physical activity: Vigorous intensity physical activity (PA)Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomizationChanges in patient-reported weekly duration of vigorous intensity PA, assessed using the International Physical Activity Questionnaire (IPAQ)
3-years cancer-specific survivalRandomization to 3 years after randomizationProportion of patients who have not died from colorectal cancer 3 years after randomization
3-years overall survivalRandomization to 3 years after randomizationProportion of patients who are alive 3 years after randomization
Carcinoembryonic antigen (CEA)Baseline, postoperative day 15, 8 weeks after dischargeChanges in blood CEA
Circulating tumor DNA (ctDNA)Baseline, postoperative day 15, 8 weeks after dischargeChanges in blood ctDNA
DNA methylationBaseline, 3 days before surgery, 1 h before anesthesia, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15, 8 weeks after dischargeChanges in DNA methylation
Exercise feasibility: Exercise sessions attendance rateFrom baseline to 8 weeks after dischargeExercise sessions attendance rate (%), defined as number of attended exercise sessions / number of prescribed exercise sessions x 100
Exercise feasibility: Relative dose intensity (RDI) of exerciseFrom baseline to 8 weeks after dischargeRDI (%) of exercise, defined as prescribed exercise dose / performed exercise dose x 100
Exercise feasibility: Early termination of exercise sessionsFrom baseline to 8 weeks after dischargeIncidence of early termination of attended exercise sessions, defined as termination of an exercise session before the prescribed exercises have been performed
Exercise feasibility: Exercise intervention interruptionsFrom baseline to 8 weeks after dischargeIncidence of exercise intervention disruptions, defined as a period of ≥ 7 days without an attended exercise session
Exercise feasibility: Exercise sessions requiring dose modificationsFrom baseline to 8 weeks after dischargeIncidence of exercise sessions requiring dose modifications, defined as any deviation from the prescribed exercise
Exercise feasibility: Permanent discontinuation of the exercise interventionFrom baseline to 8 weeks after dischargeIncidence of permanent discontinuations of the exercise intervention, defined as participants that withdraw entirely from the exercise intervention, regardless of whether they remain in the trial
Exercise feasibility: Time from discharge to initiation of postoperative exerciseFrom surgery to 8 weeks after dischargeTime from discharge to first attended postoperative exercise session
Exercise feasibility: Patient-reported symptomatic adverse events (paint, dizziness, nausea, fatigue, other)Immediately before and immediately after each exercise session performed from baseline to 8 weeks after dischargeChanges in patient-reported symptomatic adverse events (paint, dizziness, nausea, fatigue, other)
Body composition and anthropometrics: Total fat massBaseline, 8 weeks after dischargeChanges in total fat mass, assessed by DXA
Intraoperative factors: Blood loss during surgeryDuring surgeryBlood loss during surgery
Intraoperative factors: Duration of surgeryDuring surgeryDuration of surgery
Intraoperative factors: Blood transfusionsDuring surgeryIncidence of blood transfusions

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026